This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[1]
^ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]" (in Chinese). Zhonghua Bing Li Xue Za Zhi34 (11): 711–5. PMID 16536313.
Further reading
Schneider C, Hübinger G (2003). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family.". Leuk. Lymphoma43 (7): 1355–66. PMID 12389614.
Horie R, Higashihara M, Watanabe T (2003). "Hodgkin's lymphoma and CD30 signal transduction.". Int. J. Hematol.77 (1): 37–47. PMID 12568298.
Tarkowski M (2004). "Expression and a role of CD30 in regulation of T-cell activity.". Curr. Opin. Hematol.10 (4): 267–71. PMID 12799531.
Granados S, Hwang ST (2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases.". J. Invest. Dermatol.122 (6): 1345–7. doi:10.1111/j.0022-202X.2004.22616.x. PMID 15175022.
Dürkop H, Latza U, Hummel M, et al. (1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.". Cell68 (3): 421–7. PMID 1310894.
Fonatsch C, Latza U, Dürkop H, et al. (1992). "Assignment of the human CD30 (Ki-1) gene to 1p36.". Genomics14 (3): 825–6. PMID 1330892.
Josimovic-Alasevic O, Dürkop H, Schwarting R, et al. (1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay.". Eur. J. Immunol.19 (1): 157–62. PMID 2537734.
Stein H, Gerdes J, Schwab U, et al. (1983). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.". Int. J. Cancer30 (4): 445–59. PMID 6754630.
Jung W, Krueger S, Renner C, et al. (1995). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources.". Mol. Immunol.31 (17): 1329–34. PMID 7527901.
Shiota M, Fujimoto J, Semba T, et al. (1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3.". Oncogene9 (6): 1567–74. PMID 8183550.
Lee SY, Park CG, Choi Y (1996). "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors.". J. Exp. Med.183 (2): 669–74. PMID 8627180.
Gedrich RW, Gilfillan MC, Duckett CS, et al. (1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins.". J. Biol. Chem.271 (22): 12852–8. PMID 8662842.
Horie R, Ito K, Tatewaki M, et al. (1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages.". Blood88 (7): 2422–32. PMID 8839832.
Ansieau S, Scheffrahn I, Mosialos G, et al. (1997). "Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation.". Proc. Natl. Acad. Sci. U.S.A.93 (24): 14053–8. PMID 8943059.
Aizawa S, Nakano H, Ishida T, et al. (1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation.". J. Biol. Chem.272 (4): 2042–5. PMID 8999898.
Lee SY, Lee SY, Choi Y (1997). "TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation.". J. Exp. Med.185 (7): 1275–85. PMID 9104814.
Boucher LM, Marengère LE, Lu Y, et al. (1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily.". Biochem. Biophys. Res. Commun.233 (3): 592–600. doi:10.1006/bbrc.1997.6509. PMID 9168896.
Duckett CS, Thompson CB (1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival.". Genes Dev.11 (21): 2810–21. PMID 9353251.
Mizushima S, Fujita M, Ishida T, et al. (1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5).". Gene207 (2): 135–40. PMID 9511754.
Kurts C, Carbone FR, Krummel MF, et al. (1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.". Nature398 (6725): 341–4. doi:10.1038/18692. PMID 10192335.